Early serum hepatitis B virus large surface protein level: A stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B

Journal of Clinical Virology

Volumn 57, Issue 4, 2013, Pages 318-322

  Zhu, Xuejuan ^a   Gong, Qiming ^a   Yu, Demin ^a   Zhang, Donghua ^a   Gu, Leilei ^a   Han, Yue ^a   Chen, Jia ^a   Zhang, Yan ^b   Zhang, Xinxin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Chinese National Human Genome Center at Shanghai   (China)

Author keywords

Entecavir; HBsAg; Hepatitis B; Hepatitis B virus large surface protein; Peginterferon alfa 2a; Predictor

Indexed keywords

ENTECAVIR; HEPATITIS B VIRUS LARGE SURFACE PROTEIN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SERUM;

EID: 84879264338     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.04.003     Document Type: Article

References (20)

1. Ying C., Li Y., Leung C.H., Robek M.D., Cheng Y.C. Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc Natl Acad Sci USA 2007, 104:8526-8531.
2. Lai C.L., Ratziu V., Yuen M.F., Poynard T. Viral hepatitis B. Lancet 2003, 362:2089-2094.
3. Gerin J.L., Ford E.C., Purcell R.H. Biochemical characterization of Australia antigen. Evidence for defective particles of hepatitis B virus. Am J Pathol 1975, 81:651-668.
4. Hruska J.F., Robinson W.S. The proteins of hepatitis B Dane particle cores. J Med Virol 1977, 1:119-131.
5. Bruss V. Envelopment of the hepatitis B virus nucleocapsid. Virus Res 2004, 106:199-209.
6. Marquardt O., Heermann K.H., Seifer M., Gerlich W.H. Cell type specific expression of pre-S1 antigen and secretion of hepatitis B virus surface antigen. Brief report. Arch Virol 1987, 96:249-256.
7. Moucari R., Mackiewicz V., Lada O., Ripault M.P., Castelnau C., Martinot-Peignoux M., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49:1151-1157.
8. Brunetto M.R., Moriconi F., Bonino F., Lau G.K., Farci P., Yurdaydin C., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49:1141-1150.
9. Lee J.M., Ahn S.H., Kim H.S., Park H., Chang H.Y., Kim do Y., et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011, 53:1486-1493.
10. Peng C.Y., Lai H.C., Li Y.F., Su W.P., Chuang P.H., Kao J.T. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2012, 35:458-468.
11. Ma H., Yang R.F., Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J Gastroenterol Hepatol 2010, 25:1498-1506.
12. Chan H.L., Wong V.W., Chim A.M., Chan H.Y., Wong G.L., Sung J.J. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010, 32:1323-1331.
13. Chan H.L., Thompson A., Martinot-Peignoux M., Piratvisuth T., Cornberg M., Brunetto M.R., et al. Hepatitis B: surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011, 55:1121-1131.
14. Wang N.Y., Zhang D., Zhao W., Li B.A., Lin C.Q., Hepatitis B virus large surface protein in serum as a candidate biomarker for evaluating hepatitis B virus infection. Clin Biochem 2011, 44:1199-1204.
15. Dienes H.P., Gerlich W.H., Worsdorfer M., Gerken G., Bianchi L., Hess G., et al. Hepatic expression patterns of the large and middle hepatitis B virus surface proteins in viremic and nonviremic chronic hepatitis B. Gastroenterology 1990, 98:1017-1023.
16. Lau J.Y., Bain V.G., Davies S.E., Alexander G.J., Williams R. Export of intracellular HBsAg in chronic hepatitis B virus infection is related to viral replication. Hepatology 1991, 14:416-421.
17. Wang H.C., Wu H.C., Chen C.F., Fausto N., Lei H.Y., Su I.J. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol 2003, 163:2441-2449.
18. Khan N., Guarnieri M., Ahn S.H., Li J., Zhou Y., Bang G., et al. Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. J Virol 2004, 78:3262-3270.
19. Fan X., Fang D., Bin D., Xueyong L., Jun C., Hongshan W. Serum levels of surface large envelope proteins: prognostic markers for hepatitis B e antigen-negative patients with adefovir dipivoxil treatment. Antivir Ther 2009, 14:1149-1156.
20. Haruna Y., Hayashi N., Yuki N., Kasahara A., Fusamoto H., Kamada T. Serum pre-S1 and pre-S2 antigens as prognostic markers in interferon therapy for chronic hepatitis B. Scand J Gastroenterol 1992, 27:615-619.